Registry of Hospitalized Patients Treated With Fondaparinux

Completed

• Conditions: Deep Vein Thrombosis; Pulmonary Embolism

• Registration Number: NCT00549705
• Lead Sponsor: Brigham and Women's Hospital

Brief Summary

Registry of Hospitalized patients at Brigham and Women's Hospital treated with Fondaparinux

Detailed Description

The use of antithrombotic agents in the hospital is the mainstay of therapy for the treatment or prophylaxis of venous thromboembolism (VTE) and acute coronary syndrome (ACS). Concern with the administration of heparins and risk for adverse sequelae has led to the development of newer, longer-acting agents. Fondaparinux offers once daily administration with only an extremely small risk of developing heparin induced thrombocytopenia.

Recent data have further demonstrated the efficacy and safety of Fondaparinux in VTE and ACS, expanding its use in clinical practice. We aim to: 1) determine how Fondaparinux is being used in a "real life" clinical setting, a tertiary-care academic medical center (BWH), and 2) assess the associated clinical outcomes at 90 days after initiation of Fondaparinux.

Study Timeline

• Study Start: 2007-07
• Study First Submitted: 2007-10-24
• Study First Submitted QC: 2007-10-25
• Study First Posted: 2007-10-26
• Primary Completion: 2009-06
• Study Completion: 2009-06
• Status Verified: 2009-09
• Last Update Submitted: 2009-09-15
• Last Update Posted: 2009-09-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

• BWH hospitalized patients receiving Fondaparinux

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Venous Thromboembolism and Bleeding Events	90 Days

Secondary Outcome Measures

Name	Time	Method
Mortality	30 Days